Dominari (NASDAQ:DOMH – Get Free Report) and Integrated BioPharma (OTCMKTS:INBP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Valuation & Earnings
This table compares Dominari and Integrated BioPharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dominari | $123.10 million | 0.57 | -$22.43 million | ($4.03) | -0.77 |
| Integrated BioPharma | $54.35 million | 0.10 | $810,000.00 | ($0.07) | -2.58 |
Risk & Volatility
Dominari has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Integrated BioPharma has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.
Profitability
This table compares Dominari and Integrated BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dominari | -31.37% | -206.20% | -155.26% |
| Integrated BioPharma | -3.43% | -8.32% | -6.57% |
Analyst Ratings
This is a summary of current recommendations and price targets for Dominari and Integrated BioPharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dominari | 1 | 0 | 0 | 0 | 1.00 |
| Integrated BioPharma | 0 | 0 | 0 | 0 | 0.00 |
Insider and Institutional Ownership
42.5% of Dominari shares are held by institutional investors. Comparatively, 25.3% of Integrated BioPharma shares are held by institutional investors. 55.3% of Dominari shares are held by insiders. Comparatively, 67.4% of Integrated BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
About Integrated BioPharma
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.
